BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Banerjee R, Pal P, Mak JWY, Ng SC. Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia. Lancet Gastroenterol Hepatol 2020;5:1076-88. [PMID: 33181087 DOI: 10.1016/S2468-1253(20)30299-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Banerjee R, Pal P. Distinguishing intestinal tuberculosis from Crohn's disease - Authors' reply. Lancet Gastroenterol Hepatol 2021;6:159-60. [PMID: 33581751 DOI: 10.1016/S2468-1253(21)00022-4] [Reference Citation Analysis]
2 Banerjee R, Raghunathan N. Editorial: a paradigm shift in NUDT15 assessment-towards predictive and personalised medicine in Crohn's disease? Aliment Pharmacol Ther 2022;55:740-1. [PMID: 35245954 DOI: 10.1111/apt.16798] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Banerjee R, Pal P. Endoscopic Evaluation and Therapeutic Considerations of Small Bowel Crohn’s Disease. Gastroenterology Insights 2021;12:238-58. [DOI: 10.3390/gastroent12020021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Wang L, Chen L, Wang X, Liu K, Li T, Yu Y, Han J, Xing S, Xu J, Tian D, Seidler U, Xiao F. Development of a Convolutional Neural Network-Based Colonoscopy Image Assessment Model for Differentiating Crohn’s Disease and Ulcerative Colitis. Front Med 2022;9:789862. [DOI: 10.3389/fmed.2022.789862] [Reference Citation Analysis]
5 Lee WS, Song ZL, Wong SY, Gan CW, Koay ZL, Em JM, Chong SY, Lim CB, Wong SY, Chew KS, Kam CC. Environmental risk factors for inflammatory bowel disease: A case control study in Southeast Asian children. J Paediatr Child Health 2021. [PMID: 34761458 DOI: 10.1111/jpc.15830] [Reference Citation Analysis]
6 Zu M, Ma Y, Cannup B, Xie D, Jung Y, Zhang J, Yang C, Gao F, Merlin D, Xiao B. Oral delivery of natural active small molecules by polymeric nanoparticles for the treatment of inflammatory bowel diseases. Adv Drug Deliv Rev 2021;176:113887. [PMID: 34314785 DOI: 10.1016/j.addr.2021.113887] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 19.0] [Reference Citation Analysis]